Literature DB >> 26923329

The molecular mechanics of mixed lineage leukemia.

R K Slany1.   

Abstract

Mixed lineage leukemia caused by MLL fusion proteins is still a mostly incurable disease. Research on novel treatment strategies has gained momentum in the last years with the elucidation of the molecular mechanisms underlying the transforming potential of these powerful oncoproteins. This review summarizes the recent developments in this area including new attempts to treat MLL in a rational way by exploiting the biochemical vulnerabilities of the leukemogenic process.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26923329     DOI： 10.1038/onc.2016.30

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  129 in total

1.  Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription.

Authors:  Pei-Yun Chang; Robert A Hom; Catherine A Musselman; Li Zhu; Alex Kuo; Or Gozani; Tatiana G Kutateladze; Michael L Cleary
Journal:  J Mol Biol       Date:  2010-05-07       Impact factor: 5.469

Review 2.  Transcriptional regulation by Polycomb group proteins.

Authors:  Luciano Di Croce; Kristian Helin
Journal:  Nat Struct Mol Biol       Date:  2013-10       Impact factor: 15.369

3.  Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity.

Authors:  Ian G Cowell; Zbyslaw Sondka; Kayleigh Smith; Ka Cheong Lee; Catriona M Manville; Malgorzata Sidorczuk-Lesthuruge; Holly Ashlene Rance; Kay Padget; Graham Hunter Jackson; Noritaka Adachi; Caroline A Austin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

4.  Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party.

Authors:  J M Chessells; C J Harrison; H Kempski; D K H Webb; K Wheatley; I M Hann; R F Stevens; G Harrison; B E Gibson
Journal:  Leukemia       Date:  2002-05       Impact factor: 11.528

Review 5.  Treatment of infant leukemias: challenge and promise.

Authors:  Patrick Brown
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

6.  MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.

Authors:  Sara C Monroe; Stephanie Y Jo; Daniel S Sanders; Venkatesha Basrur; Kojo S Elenitoba-Johnson; Robert K Slany; Jay L Hess
Journal:  Exp Hematol       Date:  2010-09-18       Impact factor: 3.084

7.  Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.

Authors:  Han Liu; Todd D Westergard; Amanda Cashen; David R Piwnica-Worms; Lori Kunkle; Ravi Vij; Can G Pham; John DiPersio; Emily H Cheng; James J Hsieh
Journal:  Cancer Cell       Date:  2014-04-14       Impact factor: 31.743

8.  Lineage heterogeneity in acute leukemia with the t(4;11) abnormality: implications for acute mixed lineage leukemia.

Authors:  C C Childs; C Hirsch-Ginsberg; S J Culbert; M Ahearn; J Reuben; J M Trujillo; A Cork; R R Walters; E J Freireich; S A Stass
Journal:  Hematol Pathol       Date:  1988

9.  Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties.

Authors:  Akihiko Yokoyama; Issay Kitabayashi; Paul M Ayton; Michael L Cleary; Misao Ohki
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

10.  High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction.

Authors:  Shihan He; Timothy J Senter; Jonathan Pollock; Changho Han; Sunil Kumar Upadhyay; Trupta Purohit; Rocco D Gogliotti; Craig W Lindsley; Tomasz Cierpicki; Shaun R Stauffer; Jolanta Grembecka
Journal:  J Med Chem       Date:  2014-02-06       Impact factor: 7.446
View more
  36 in total

1.  Targeting acute myeloid leukemia by drug-induced c-MYB degradation.

Authors:  V Walf-Vorderwülbecke; K Pearce; T Brooks; M Hubank; M M van den Heuvel-Eibrink; C M Zwaan; S Adams; D Edwards; J Bartram; S Samarasinghe; P Ancliff; A Khwaja; N Goulden; G Williams; J de Boer; O Williams
Journal:  Leukemia       Date:  2017-11-01       Impact factor: 11.528

2.  Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias.

Authors:  Zhen-Tang Lao; Ling-Wen Ding; Omer An; Norimichi Hattori; Qiao-Yang Sun; Kar-Tong Tan; Anand Mayakonda; Wong Gee Chuan; Vikas Madan; De-Chen Lin; Henry Yang; H Phillip Koeffler
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

Review 3.  COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer.

Authors:  Richard J Fagan; Andrew K Dingwall
Journal:  Cancer Lett       Date:  2019-05-22       Impact factor: 8.679

Review 4.  Mature lymphoid malignancies: origin, stem cells, and chronicity.

Authors:  Simon Husby; Kirsten Grønbæk
Journal:  Blood Adv       Date:  2017-11-28

5.  C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.

Authors:  A E Marneth; K H M Prange; A S A Al Hinai; S M Bergevoet; N Tesi; E M Janssen-Megens; B Kim; N Sharifi; M L Yaspo; J Kuster; M A Sanders; E C G Stoetman; J Knijnenburg; T C J M Arentsen-Peters; C M Zwaan; H G Stunnenberg; M M van den Heuvel-Eibrink; T Haferlach; M Fornerod; J H Jansen; P J M Valk; B A van der Reijden; J H A Martens
Journal:  Leukemia       Date:  2017-09-05       Impact factor: 11.528

6.  Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.

Authors:  Yufei Chen; Patricia Ernst
Journal:  Cell Cycle       Date:  2019-06-04       Impact factor: 4.534

7.  Exploitable metabolic dependencies in MLL-ENL-induced leukemia.

Authors:  Maria-Paz Garcia-Cuellar; Jennifer Lawlor; Martin Böttcher; Dimitrios Mougiakakos; Markus Metzler; Robert K Slany
Journal:  Blood Adv       Date:  2020-08-11

8.  Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.

Authors:  Manuela Sabatino; Dante Rotili; Alexandros Patsilinakos; Mariantonietta Forgione; Daniela Tomaselli; Fréderic Alby; Paola B Arimondo; Antonello Mai; Rino Ragno
Journal:  J Comput Aided Mol Des       Date:  2018-01-15       Impact factor: 3.686

9.  SETD2 in MLL-rearranged leukemia - a complex case.

Authors:  Anna Skucha; Jessica Ebner; Florian Grebien
Journal:  Mol Cell Oncol       Date:  2018-08-13

10.  A molecular study of synovial chondromatosis.

Authors:  Narasimhan P Agaram; Lei Zhang; Brendan C Dickson; David Swanson; Yun-Shao Sung; David M Panicek; Meera Hameed; John H Healey; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2019-10-18       Impact factor: 5.006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.